Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04918030
Other study ID # 2020YLK14
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 11, 2021
Est. completion date May 1, 2023

Study information

Verified date October 2022
Source Xiamen Cardiovascular Hospital, Xiamen University
Contact Xiang Chen, Dr
Phone 18033997788
Email Seanchenx@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with STEMI and MVD Objectives: The present study aimed to investigate the difference in all-cause mortality after in-hospital staged PCI versus out-hospital staged PCI for ST-segment elevated myocardial infarction (STEMI)patients with multi-vessel Disease(MVD) Background: In primary percutaneous coronary intervention for STEMI with MVD, complete revascularization has proved to reduce the risk of cardiovascular death and myocardial infarction. However, a strategy of nonculprit-vessel PCI with the goal of complete revascularization still not to be confirmed. Compare with in-hospital staged PCI, out-hospital PCI as a strategy of nonculprit-vessel PCI for STEMI patients with MVD might have be beneficial results.


Description:

A total of 1700 subjects with STEMI who met inclusion criteria and do not have any exclusion criterion will be randomized to in-hospital staged PCI group and out-hospital staged PCI group. After successful percutaneous coronary intervention for culprit lesion, all non-culprit vessel with significant lesion defined at least 80% diameter stenosis by visual estimation and accompanied by a QFR measurement of less than or equal to 0.80 will be performed complete revascularization. 1. Patients randomized to in-hospital staged PCI will have treated during the index procedure (7±3 days), after revascularization of the culprit lesion, all significant non-culprit coronary lesions. 2. Patients randomized to out-hospital staged complete revascularization will have treated during the index procedure only the culprit lesion, and they will be hospitalized in 30±15 days for complete revascularization of all significant non-culprit coronary lesions.


Recruitment information / eligibility

Status Recruiting
Enrollment 1700
Est. completion date May 1, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Provision of informed consent prior to any study specific procedures; - Established indication to PPCI according to the guidelines of American Heart Association and American College of Cardiology; - Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset) with MVD after successful revascularization of the culprit artery; - De novo coronary lesion, - TIMI Flow 3 ( Cases with TIMI flow 2 need to perform angiographic again in 24h ensured TIMI flow 3 for enrolling case )after revascularization of the culprit artery, residual stenosis =20% and no coronary dissection greater than or equal to type C leading to (threatening) vessel closure. - At least one non-culprit coronary stenosis = 80% and accompanied by QFR =0.8 in a vessel with a lumen diameter =2.5; Exclusion Criteria: - Age <18 yr and >80 yr; - Cardiac shock, multiple organ failure, cerebral hemorrhage, severe aortic stenosis and myocardial infarction complications(cardiac rupture, ventricular septal rupture and papillary muscle rupture); - Killip classification >3, cardiognic shock, shore-infarction of culprit artery after emergency PCI in 24 hours; - Previous documented allergic reaction to drug and device of this study; - Planned major surgery within 6 weeks in which impact DAPT; - Participation in another clinical study, interfering with this protocol Uncertain; - Life expectancy < 1 year; - Any condition likely to interfere with study processes including follow-up visits or increase of risk accessed by researcher.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
In-hospital staged PCI
After revascularization of the culprit lesion, all significant non-culprit vessel will be complete revascularzed during index the index procedure (7±3 day).
Out-hospital staged PCI
During the index procedure, patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 30±15 days to undergo PCI of the other significant coronary lesions.

Locations

Country Name City State
China Xiamen Cardiovascular Hospital Xiamen University Xiamen Fujian

Sponsors (1)

Lead Sponsor Collaborator
Xiamen Cardiovascular Hospital, Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary all-cause mortality The difference in all-cause mortality will be calculated from 0 month to 12 months. 12 months
Secondary Major adverse cardiovascular and cerebrovascular events (MACE) The difference in MACCE will be calculated from 1 month to 12 months. 12 months
Secondary Rate of Stroke 12 months
Secondary Rate of contrast-induced nephropathy(CIN) 12 months
Secondary Dosimetry calculation(The amount of X-ray exposure shown by the DSA) The amount of X-ray exposure shown by the DSA Immediately after PCI
See also
  Status Clinical Trial Phase
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05240781 - Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk N/A
Recruiting NCT03378934 - Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention Phase 4
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Completed NCT03085823 - The All-comers Sirolimus-coated Balloon European Registry
Completed NCT02837744 - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed NCT02044146 - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk Phase 2/Phase 3
Completed NCT03131271 - Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention N/A
Completed NCT01135667 - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI Phase 4
Completed NCT01156571 - A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Phase 3
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00725868 - Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention N/A
Completed NCT03708588 - Chewed Versus Integral Pill of Ticagrelor Phase 4
Completed NCT04163393 - R-One Efficiency For PCI Evolution With Robotic Assistance N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT06080919 - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI). N/A
Recruiting NCT05353140 - LAAO Versus NOAC in Patients With AF and PCI N/A